FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumor
Recommended
FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumor
The FDA approved sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->